US 12,268,671 B2
IL-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy
Laura Brandolini, L'Aquila (IT); Pier Adelchi Ruffini, Milan (IT); and Marcello Allegretti, Rome (IT)
Assigned to DOMPÉ FARMACEUTICI S.P.A., Milan (IT)
Appl. No. 16/066,072
Filed by DOMPÉ FARMACEUTICI S.P.A., Milan (IT)
PCT Filed Jan. 13, 2017, PCT No. PCT/EP2017/050637
§ 371(c)(1), (2) Date Jun. 26, 2018,
PCT Pub. No. WO2017/121838, PCT Pub. Date Jul. 20, 2017.
Claims priority of application No. 16151618 (EP), filed on Jan. 15, 2016; and application No. 16190871 (EP), filed on Sep. 27, 2016.
Prior Publication US 2019/0015391 A1, Jan. 17, 2019
Int. Cl. A61K 31/165 (2006.01); A61K 31/18 (2006.01); A61K 31/19 (2006.01); A61K 31/192 (2006.01); A61K 31/426 (2006.01); A61P 25/00 (2006.01); A61P 25/02 (2006.01); A61P 27/02 (2006.01)
CPC A61K 31/426 (2013.01) [A61K 31/165 (2013.01); A61K 31/19 (2013.01); A61K 31/192 (2013.01); A61P 25/02 (2018.01)] 16 Claims
 
1. A method of treating and/or preventing chemotherapy-induced neuropathy, wherein the chemotherapy-induced neuropathy is chemotherapy-induced peripheral neuropathy or chemotherapy-induced optic neuropathy and wherein the chemotherapy-induced neuropathy is induced by a chemotherapeutic agent selected from the group consisting of taxanes and platinum based drugs, in a subject in need thereof, comprising administration of an IL-8 inhibitor, wherein the IL-8 inhibitor is a compound of formula (II)

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
wherein:
R4 is linear or branched C1-C6 alkyl, benzoyl, phenoxy, or trifluoromethanesulfonyloxy;
R5 is H or linear or branched C1-C3 alkyl;
R6 is linear or branched C1-C6 alkyl or trifluoromethyl.